532 related articles for article (PubMed ID: 24918373)
1. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis.
Mease PJ; Genovese MC; Greenwald MW; Ritchlin CT; Beaulieu AD; Deodhar A; Newmark R; Feng J; Erondu N; Nirula A
N Engl J Med; 2014 Jun; 370(24):2295-306. PubMed ID: 24918373
[TBL] [Abstract][Full Text] [Related]
2. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.
Papp KA; Leonardi C; Menter A; Ortonne JP; Krueger JG; Kricorian G; Aras G; Li J; Russell CB; Thompson EH; Baumgartner S
N Engl J Med; 2012 Mar; 366(13):1181-9. PubMed ID: 22455412
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.
Genovese MC; Mease PJ; Thomson GT; Kivitz AJ; Perdok RJ; Weinberg MA; Medich J; Sasso EH;
J Rheumatol; 2007 May; 34(5):1040-50. PubMed ID: 17444593
[TBL] [Abstract][Full Text] [Related]
4. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
Spuls PI; Hooft L
Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
[TBL] [Abstract][Full Text] [Related]
5. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
Lebwohl M; Strober B; Menter A; Gordon K; Weglowska J; Puig L; Papp K; Spelman L; Toth D; Kerdel F; Armstrong AW; Stingl G; Kimball AB; Bachelez H; Wu JJ; Crowley J; Langley RG; Blicharski T; Paul C; Lacour JP; Tyring S; Kircik L; Chimenti S; Callis Duffin K; Bagel J; Koo J; Aras G; Li J; Song W; Milmont CE; Shi Y; Erondu N; Klekotka P; Kotzin B; Nirula A
N Engl J Med; 2015 Oct; 373(14):1318-28. PubMed ID: 26422722
[TBL] [Abstract][Full Text] [Related]
6. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
[TBL] [Abstract][Full Text] [Related]
7. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
[TBL] [Abstract][Full Text] [Related]
8. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study.
Nakagawa H; Niiro H; Ootaki K;
J Dermatol Sci; 2016 Jan; 81(1):44-52. PubMed ID: 26547109
[TBL] [Abstract][Full Text] [Related]
9. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.
Mease PJ; McInnes IB; Kirkham B; Kavanaugh A; Rahman P; van der Heijde D; Landewé R; Nash P; Pricop L; Yuan J; Richards HB; Mpofu S;
N Engl J Med; 2015 Oct; 373(14):1329-39. PubMed ID: 26422723
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
Gladman DD; Mease PJ; Ritchlin CT; Choy EH; Sharp JT; Ory PA; Perdok RJ; Sasso EH
Arthritis Rheum; 2007 Feb; 56(2):476-88. PubMed ID: 17265483
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.
Deodhar A; Gottlieb AB; Boehncke WH; Dong B; Wang Y; Zhuang Y; Barchuk W; Xu XL; Hsia EC;
Lancet; 2018 Jun; 391(10136):2213-2224. PubMed ID: 29893222
[TBL] [Abstract][Full Text] [Related]
12. A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis.
Martin DA; Churchill M; Flores-Suarez L; Cardiel MH; Wallace D; Martin R; Phillips K; Kaine JL; Dong H; Salinger D; Stevens E; Russell CB; Chung JB
Arthritis Res Ther; 2013 Oct; 15(5):R164. PubMed ID: 24286136
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
Choy EH; Isenberg DA; Garrood T; Farrow S; Ioannou Y; Bird H; Cheung N; Williams B; Hazleman B; Price R; Yoshizaki K; Nishimoto N; Kishimoto T; Panayi GS
Arthritis Rheum; 2002 Dec; 46(12):3143-50. PubMed ID: 12483717
[TBL] [Abstract][Full Text] [Related]
14. A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate.
Genovese MC; Lee E; Satterwhite J; Veenhuizen M; Disch D; Berclaz PY; Myers S; Sides G; Benichou O
Ann Rheum Dis; 2013 Sep; 72(9):1453-60. PubMed ID: 23599435
[TBL] [Abstract][Full Text] [Related]
15. Improvement in Psoriasis Signs and Symptoms Assessed by the Psoriasis Symptom Inventory with Brodalumab Treatment in Patients with Psoriatic Arthritis.
Mease PJ; Genovese MC; Mutebi A; Viswanathan HN; Chau D; Feng J; Erondu N; Nirula A
J Rheumatol; 2016 Feb; 43(2):343-9. PubMed ID: 26773108
[TBL] [Abstract][Full Text] [Related]
16. Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials.
Mease PJ; Helliwell PS; Hjuler KF; Raymond K; McInnes I
Ann Rheum Dis; 2021 Feb; 80(2):185-193. PubMed ID: 33106286
[TBL] [Abstract][Full Text] [Related]
17. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.
Lovell DJ; Ruperto N; Goodman S; Reiff A; Jung L; Jarosova K; Nemcova D; Mouy R; Sandborg C; Bohnsack J; Elewaut D; Foeldvari I; Gerloni V; Rovensky J; Minden K; Vehe RK; Weiner LW; Horneff G; Huppertz HI; Olson NY; Medich JR; Carcereri-De-Prati R; McIlraith MJ; Giannini EH; Martini A; ;
N Engl J Med; 2008 Aug; 359(8):810-20. PubMed ID: 18716298
[TBL] [Abstract][Full Text] [Related]
18. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
McInnes IB; Mease PJ; Kirkham B; Kavanaugh A; Ritchlin CT; Rahman P; van der Heijde D; Landewé R; Conaghan PG; Gottlieb AB; Richards H; Pricop L; Ligozio G; Patekar M; Mpofu S;
Lancet; 2015 Sep; 386(9999):1137-46. PubMed ID: 26135703
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment.
Papp K; Leonardi C; Menter A; Thompson EH; Milmont CE; Kricorian G; Nirula A; Klekotka P
J Am Acad Dermatol; 2014 Dec; 71(6):1183-1190.e3. PubMed ID: 25313095
[TBL] [Abstract][Full Text] [Related]
20. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study.
Schett G; Wollenhaupt J; Papp K; Joos R; Rodrigues JF; Vessey AR; Hu C; Stevens R; de Vlam KL
Arthritis Rheum; 2012 Oct; 64(10):3156-67. PubMed ID: 22806399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]